Good decisions require good information
Find hidden gems and smart strategies from top experts when you join Seeking Alpha.
CYTH Cyclo Therapeutics, Inc.Stock Price & Overview
$1.28
Charts
Quant Ranking
CYTH Analysis
CYTH News
Latest Headlines
Ratings Summary
People Also Follow
Similar to CYTH
ETFs Holding CYTH
CYTH Company Profile
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company’s lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer’s disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.
CYTH Revenue
CYTH Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Growth
Profitability
Momentum
Capital Structure
Dividends
CYTH Ownership
CYTH Peers
Risk
Technicals
Investor Presentations
CYTH SEC Filings
Press Releases
CYTH Income Statement
CYTH Balance Sheet
CYTH Cash Flow Statement
CYTH Long Term Solvency
Discover More
You may be interested in: